GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (NAS:XNCR) » Definitions » Price-to-Tangible-Book

XNCR (Xencor) Price-to-Tangible-Book : 2.50 (As of Dec. 11, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Xencor Price-to-Tangible-Book?

As of today (2024-12-11), Xencor's share price is $25.26. Xencor's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was $10.09. Hence, Xencor's Price to Tangible Book Ratio of today is 2.50.

The historical rank and industry rank for Xencor's Price-to-Tangible-Book or its related term are showing as below:

XNCR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.88   Med: 3.38   Max: 10.05
Current: 2.5

During the past 13 years, Xencor's highest Price to Tangible Book Ratio was 10.05. The lowest was 1.88. And the median was 3.38.

XNCR's Price-to-Tangible-Book is ranked better than
56.03% of 1203 companies
in the Biotechnology industry
Industry Median: 2.9 vs XNCR: 2.50

A closely related ratio is called PB Ratio. As of today, Xencor's share price is $25.26. Xencor's Book Value per Sharefor the quarter that ended in Sep. 2024 was $10.35. Hence, Xencor's P/B Ratio of today is 2.44.


Xencor Price-to-Tangible-Book Historical Data

The historical data trend for Xencor's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xencor Price-to-Tangible-Book Chart

Xencor Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.38 4.54 3.32 2.20 1.99

Xencor Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.88 1.99 2.30 2.14 1.99

Competitive Comparison of Xencor's Price-to-Tangible-Book

For the Biotechnology subindustry, Xencor's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xencor's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xencor's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Xencor's Price-to-Tangible-Book falls into.



Xencor Price-to-Tangible-Book Calculation

Xencor's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2024 )
=25.26/10.09
=2.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Xencor Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Xencor's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Xencor Business Description

Traded in Other Exchanges
Address
465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Executives
Alan Bruce Montgomery director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Bassil I Dahiyat director, officer: PRESIDENT & CEO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John R Desjarlais officer: SR. VICE PRESIDENT & CSO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Ellen Feigal director C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Richard J Ranieri director 3005 FIRST AVE, SEATTLE WA 98121
Kurt A Gustafson director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Kevin Charles Gorman director 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Nancy Valente director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Celia Eckert officer: VP, GENERAL COUNSEL C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John J Kuch officer: SR. VICE PRESIDENT & CFO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Allen Yang officer: SR. VICE PRESIDENT & CMO C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Stafford John S Iii 10 percent owner 230 SOUTH LASALLE STREET 400, CHICAGO IL 60604